Investors Hangout Stock Message Boards Logo
  • Mailbox
  • Favorites
  • Boards
    • The Hangout
    • NASDAQ
    • NYSE
    • OTC Markets
    • All Boards
  • Whats Hot!
    • Recent Activity
    • Most Viewed Boards
    • Most Viewed Posts
    • Most Posted
    • Most Followed
    • Top Boards
    • Newest Boards
    • Newest Members
  • Blog
    • Recent Blog Posts
    • Recently Updated
    • News
    • Stocks
    • Crypto
    • Investing
    • Business
    • Markets
    • Economy
    • Real Estate
    • Personal Finance
  • Market Movers
  • Interactive Charts
  • Login - Join Now FREE!
  1. Home ›
  2. Stock Message Boards ›
  3. Stock Boards ›
  4. Amarantus Bioscience Holdings (AMBS) Message Board

Latest Publication on Elto from Sep 2021 suggests

Message Board Public Reply | Private Reply | Keep | Replies (0)                   Post New Msg
Edit Msg () | Previous | Next


Post# of 30070
(Total Views: 731)
Posted On: 02/20/2022 6:33:49 PM
Avatar
Posted By: freegriff
Latest Publication on Elto from Sep 2021 suggests pairing eltoprazine with Levadopa and Preladenant as a sort of Parkinson's cocktail. Preladenant is an Adenosine 2A Receptor Antagonist owned by Merck. Others include Vipadenant owned by Celgene, or Tozadenant, owned by Acorda, or istradefylline, owned by Kyowa Kirin in Japan. So that's more of the field of potential partners. Remember, GC may already be talking to Merck via Todos given his focus on supplanting Remsdesivir.

This study is critical because it was this same group of researchers from the National Research Council of Italy (CNR), Neuroscience Institute that put the temporary kibosh on eltoprazine in dyskinesia back in 2016 when they said that when just paired with levedopa, both drugs counteracted each other.

Neuroinflammation and L-dopa-induced abnormal involuntary movements
in 6-hydroxydopamine-lesioned rat model of Parkinson’s disease are
counteracted by combined administration of a 5-HT1A/1B receptor agonist
and A2A receptor antagonist

Pinna, A., Costa, G., Serra, M., Contu, L., & Morelli, M. (2021). Neuroinflammation and L-dopa-induced abnormal involuntary movements in 6-hydroxydopamine-lesioned rat model of Parkinson’s disease are counteracted by combined administration of a 5-HT1A/1B receptor agonist and A2A receptor antagonist. Neuropharmacology, 196, 108693. doi:10.1016/j.neuropharm.2021.108693
10.1016/j.neuropharm.2021.108693

In conclusion, the present findings show that a challenge with L-dopa
induces a reduced neuroinflammatory response in 6-OHDA-lesioned rats
pretreated with an association of A2A antagonists and 5-HT1A/1B agonists, suggesting that this drug association may be a promising therapeutic strategy for preventing both neuroinflammation and dyskinesia.


(3)
(0)




Amarantus Bioscience Holdings (AMBS) Stock Research Links


  1.  
  2.  


  3.  
  4.  
  5.  






Investors Hangout

Home

Mailbox

Message Boards

Favorites

Whats Hot

Blog

Settings

Privacy Policy

Terms and Conditions

Disclaimer

Contact Us

Whats Hot

Recent Activity

Most Viewed Boards

Most Viewed Posts

Most Posted Boards

Most Followed

Top Boards

Newest Boards

Newest Members

Investors Hangout Message Boards

Welcome To Investors Hangout

Stock Message Boards

American Stock Exchange (AMEX)

NASDAQ Stock Exchange (NASDAQ)

New York Stock Exchange (NYSE)

Penny Stocks - (OTC)

User Boards

The Hangout

Private

Global Markets

Australian Securities Exchange (ASX)

Euronext Amsterdam (AMS)

Euronext Brussels (BRU)

Euronext Lisbon (LIS)

Euronext Paris (PAR)

Foreign Exchange (FOREX)

Hong Kong Stock Exchange (HKEX)

London Stock Exchange (LSE)

Milan Stock Exchange (MLSE)

New Zealand Exchange (NZX)

Singapore Stock Exchange (SGX)

Toronto Stock Exchange (TSX)

Contact Investors Hangout

Email Us

Follow Investors Hangout

Twitter

YouTube

Facebook

Market Data powered by QuoteMedia. Copyright © 2025. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges).
Analyst Ratings & Earnings by Zacks. RT=Real-Time, EOD=End of Day, PD=Previous Day. Terms of Use.

© 2025 Copyright Investors Hangout, LLC All Rights Reserved.

Privacy Policy |Do Not Sell My Information | Terms & Conditions | Disclaimer | Help | Contact Us